Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a... see more

TSX:SVA - Post Discussion

Sernova Corp > busy times here...
View:
Post by 88STR8T on Feb 05, 2021 6:59pm

busy times here...

All this and more!!
 
Hemophilia A Gene, Cell Therapy Combo Shows Promise, Study Reports (hemophilianewstoday.com)
 
…..and this
 

Sernova’s Collaborator to Present Cell Pouch™ Thyroid Transplant Study Results at the American Association of Endocrine Surgeons 2021 Annual Meeting

February 3, 2021 - 9:00 a.m. EST

LONDON, ONTARIO – February 3, 2021 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that Dr. Sam Wiseman, BSc, MD, FRCSC, FACS of the University of British Columbia and co-investigator of Sernova’s Cell Pouch Hypothyroid treatment program will present preclinical data in an oral presentation at the American Association of Endocrine Surgeons (AAES) 2021 Annual Meeting taking place April 25-27, 2021. Dr. Sam Wiseman, Professor, Richard J. Finley Scholar, and Director of Research at the Department of Surgery of Providence Health Care also serves as Chair of the Endocrine Tumor Group for the Surgical Oncology Network in Vancouver British Columbia.

Dr. Wiseman’s abstract was selected amongst over 140 abstracts for an Oral Podium Presentation and a resulting journal article will be peer-reviewed for publication consideration in the journal Surgery.

For more information on the American Association of Endocrine Surgeons and the 41st Annual Meeting, visit https://meeting.endocrinesurgery.org/.

ABOUT SERNOVA’S HYPOTHYROID PROGRAM

Sernova’s initial approach in treating hypothyroid disease is to transplant a patient’s own healthy thyroid tissue following thyroidectomy into the pre-implanted vascularized Cell Pouch to recover the normal function of the thyroid gland. In collaboration with Dr. Wiseman, preclinical proof of concept work is being conducted under a grant from the British Columbia Transplant Foundation. Following successful completion of preclinical studies, Sernova plans to conduct clinical assessments of the Cell Pouch with transplanted thyroid tissue in patients suffering from hypothyroid disease with the aim to preserve thyroid function and improve patient quality of life.

Thyroidectomy is commonly performed for cancer diagnosis or treatment and for treatment of benign (non- cancerous) disease that includes goiter and hyperthyroidism. It is estimated that about 150,000 thyroidectomies are performed in the US yearly, and the majority of individuals undergoing a thyroid operation are diagnosed with benign diseases after their procedure. Patients with Grave’s disease and thyroid nodules undergoing total thyroidectomy, and many patients undergoing partial thyroidectomy require life-long thyroid hormone medication. Post-surgical thyroid hormone replacement therapy, if monitored carefully, can be effective; however, patients often suffer from deleterious side-effects including weight gain, depression, headaches, and cardiovascular disease, with resultant negative impact on quality of life, and significant costs to the healthcare system. The development of new therapeutic strategies to overcome hypothyroidism remains an important unmet medical need.
  
News alert…. Nice SVA BTV commercial
 
https://b-tv.com/sernova-a-functional-cure-for-type-i-diabetes-news-alert-60sec/
 
ALSO…
 
bought a deal for $20M….. oversubscribed by 100%.... and huge demand that most were not able to get in on….
 
there is lots to love and hate about this placement…I love not so much the full warrants with the deal… but this.... plus recently cashed warrants gives them more cash, $25M, than they had at one time… ever….…. Sernova has their reasons for using Cannacord.... and shared this:
 
Sigilon Therapeutics
December 2020
Canaccord Genuity Acted as a Bookrunner in an Initial Public Offering for Sigilon Therapeutics, Inc.
Transaction Overview:
Sigilon Therapeutics, Inc. (the “Company”) (Nasdaq:SGTX), priced its $126 million upsized initial public offering on December 3, 2020 at a price of $18 per share. The Company issued 7,000,000 shares of common stock. The Underwriters exercised their option to purchase an additional $1,050,000 shares of common stock at the initial public offering price, bringing the total proceeds to $144.9 million, less the underwriting discounts and commissions.

Company Overview:

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis.
 
ALSO……
Sernova Corp.'s shares have started trading on Xetra, the electronic trading system of Deutsche Borse AG in Germany …. approximately 90 percent of all trading in shares across all German exchanges is now conducted through Xetra making it the largest of Germany's stock exchanges. Over 200 trading participants from 16 European countries, United Arab Emirates and Hong Kong are connected via Xetra servers.
Xetra is the first and primary choice for institutional investors with its significantly higher liquidity and narrower price spreads. Given the high turnover (liquidity) on the Xetra trading venue, orders for securities are executed swiftly and at prices in line with the market. Moreover, this principle is supported by Designated Sponsors who post binding purchase and selling prices (quotes) continuously and thus ensure additional liquidity and fair prices, making it the first choice for institutional investors. mwb Wertpapierhandelsbank AG will act as Designated Sponsor (active market maker) to handle the trading of Sernova's shares on Xetra with immediate effect and therefore contribute to increased trading liquidity.

……APPARENTLY, the European equivalent of NASDAQ.

LOOKS PRETTY POSITIVE TO ME...HOW ABOU YOU?

oh... and I think this is a new tag at the bottom of news..... and I like it.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com
Comment by BioTeck on Feb 05, 2021 8:05pm
We haven't heard a lot about our hemophilia program since Horizon 2020.  Though I was happy with the results, it took 4 or 5 different companies to treat Hemophiliac rats/pigs/whatever . First extracting cells that produce factor 8. Then replicating, freezing,shipping, and implantation etc. I think the reason for this partly is because the cells were allografts meaning a sample taken ...more  
Comment by AlfonzoBall on Feb 05, 2021 10:24pm
Bio although my smooth brain is not capable of deciphering what you just said a quick Google search will give you the relationship between Cannacord and Sigilon. I'm sure you can make much more sense of it than me.
Comment by AlfonzoBall on Feb 05, 2021 10:28pm
https://www.canaccordgenuity.com/capital-markets/what-we-do/investment-banking/transactions/2020/december/sigilon/
Comment by Redbaron2211 on Feb 05, 2021 11:59pm
Sigilon may need Sernova but Sernova has successfully proven their own cells corrected for F8 can be replicated and scaled-up.   I haven't looked at Sigilon's coating spheres in detail but they are injected into the abdominin of the animals and seems to show some promise but all the data is preclinical not sure how they are collected and redosed it seems a little more ...more  
Comment by BioTeck on Feb 06, 2021 1:53am
Green Barron. Sernova has no hemophilia cells. Show me where you're getting this information.
Comment by fivenine on Feb 06, 2021 2:33am
  My understanding is that the patient's own blood is used to isolate and collect endothelial cells which are corrected for the factor 8 gene and then reproduced. The corrected cells are then placed in a Cell Pouch and produce factor 8 which is released into the bloodstream.
Comment by Redbaron2211 on Feb 06, 2021 6:27am
Bio its been in multiple MD&S's In summary, the following developments have been achieved by the Consortium: In blood donated from patients with Hemophilia A, blood endothelial outgrowth cells to be corrected for the Factor VIII gene were isolated and grown successfully in a specialized Good Manufacturing Process (cGMP) compliant medium developed by the Consortium. Using a human ...more  
Comment by Redbaron2211 on Feb 06, 2021 6:37am
 To be clear I'm referring to the consortium not Sernova specifically.  But they have achieved a cell production process that can be scaled up and cryopreserved.   Its possible Sigilion could be a better option but this looks promising from my observations anyways.
Comment by BioTeck on Feb 06, 2021 11:05am
So your answer is basically what I said in my original post. Sernova has no cells and they need to work with the 4 or 5 companies which you called the consortium. So back to my original post again, why work with a consortium if you can work with one company?
Comment by Redbaron2211 on Feb 07, 2021 11:07am
Bio I think the difference is I believe Sernova doesn't need Sigilon as we already have a very promising collaboration with the HemAcure consortium.  maybe your right in that it would be better to work with one company and I can agree Sigilon could be a possibility but at this point I don't really see the benefit.  This; The Device Conundrum “We thought the ...more  
Comment by BioTeck on Feb 07, 2021 6:01pm
No benefit? One company vs 4 and no need for sending patient cells all over Europe. So it's fine for them to collab with the European companies but not sigilion. Interesting logic.
Comment by Redbaron2211 on Feb 07, 2021 6:55pm
Difference is they are already in a collaboration. They can ship the cells anywhere in the world.
Comment by BioTeck on Feb 07, 2021 7:05pm
Had a collaboration you mean. Haven't heard anything about it since it ended. Let's just agree to disagree. You're clearly not seeing my point about it being a much more simple and elegant solution. Not to mention sigilon been approved to test in humans when the 2020 science was conducted on mice.
Comment by Redbaron2211 on Feb 07, 2021 8:58pm
They just completed pre-clinical proof of concept last May and from my understanding have a clinical program under development for hemophilia.   I wouldn't be surprised and expect to see that starting up anytime now.  You could be right I'm not saying there isn't potentially better options with Sigilion its all speculation we can agree to agree or disagree its all good.& ...more  
Comment by MedStocks2 on Feb 08, 2021 6:08am
@Red keep in mind that it is unlikely the FDA is going to let anyone just inject cells. SIG will still need a device.
Comment by Redbaron2211 on Feb 08, 2021 8:55am
Can't say I don't like the idea of a collaboration with Sigilion it would add yet another layer of validation not that we need it at this point. However it would come as a surprise as they have already started Recruiting for their FDA trials using the spheres. Each sphere contains thousands of cells it's not like they are just injecting cells. I don't get how the cells survive with ...more  
Comment by BioTeck on Feb 08, 2021 9:54am
Red this is hemophilia, there are no islets.
Comment by Redbaron2211 on Feb 08, 2021 9:57am
Edit: should say dosing the f8 corrected cells. Yes momentum is coming in no reason why this shouldn't be sitting at peer valuation.
Comment by Redbaron2211 on Feb 08, 2021 10:00am
Yah no kidding Bio I think thats a given, would have corrected it if stockhouse wasn't the ghetto.
Comment by Redbaron2211 on Feb 08, 2021 10:41am
Investors have to consider where our valuation should be now that it’s obvious a functional device will be the limiting factor.  Should it be trading at 1/3 of those with preclinical cells?  Something with Sigilion would be an appetizer.  Sernova is focused on the big prize diabetes.  Vertex may be interested in it for their semma cells. What puts sernova in such a powerful ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities